Behavioral Interventions for Controlling Oral Behaviors
Launched by UNIVERSITY OF TORONTO · Jun 7, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people manage oral behaviors, like teeth clenching and grinding, which can lead to jaw pain and other issues known as temporomandibular disorders (TMD). Researchers want to find out if a week-long mobile program, which reminds people in real-time about these behaviors, combined with helpful information about jaw muscle activity, can reduce these harmful habits better than just providing information alone.
To take part in this study, participants should be aged 65 to 74 and report a score of 25 or higher on a questionnaire that checks for these oral behaviors. This means they may have habits that could contribute to jaw pain. If you qualify and decide to join, you’ll learn more about your oral habits and receive support to help change them. The results of this study could lead to better treatments for those suffering from TMD and related pain.
Gender
ALL
Eligibility criteria
- • Individuals reporting a score greater than or equal to 25 on the oral behavior checklist (OBC). The OBC is a self-report questionnaire used to assess the frequency of various daytime and sleep-related oral behaviors, such as teeth clenching, grinding, and jaw tension.
- • It helps identify habits that may contribute to temporomandibular disorders (TMD) and orofacial pain.
About University Of Toronto
The University of Toronto, a prestigious research institution, serves as a leading sponsor of clinical trials dedicated to advancing medical knowledge and improving patient care. With a commitment to innovation and excellence, the university fosters a collaborative environment that brings together multidisciplinary teams of experts in medicine, pharmacology, and public health. Through rigorous research methodologies and ethical standards, the University of Toronto aims to explore new therapies, assess treatment efficacy, and address critical health challenges, ultimately contributing to the global body of scientific knowledge and enhancing healthcare outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported